Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01RNL
|
|||
| Former ID |
DIB001055
|
|||
| Drug Name |
Lintuzumab
|
|||
| Synonyms |
Zamyl; HuM195; HuM195, PDL; Humanized M195, PDL; KB-195; SGN-33; SMART M195, PDL; M195 (humanized), Protein Design Labs; Anti-CD33 mAb (leukemia), Seattle Genetics
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Discontinued in Phase 2 | [1], [2] | |
| Company |
PDL BioPharma Inc; Seattle Genetics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | . | [3] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7983). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015937) | |||
| REF 3 | Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005 Jun 20;23(18):4110-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.